Krystal Biotech, Inc.
KRYS
$180.30
-$3.62-1.97%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 423.23% | -66.34% | 146.88% | 102.06% | 127.12% |
| Total Depreciation and Amortization | -59.41% | -45.63% | 5.83% | -43.40% | 2.94% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 39.99% | 113.86% | 27.96% | -12.30% | -0.94% |
| Change in Net Operating Assets | 78.25% | 291.78% | -181.74% | -28.45% | -5,952.09% |
| Cash from Operations | 830.68% | 377.29% | 87.81% | 160.74% | 67.61% |
| Capital Expenditure | 56.63% | 41.27% | 59.46% | 76.58% | 64.60% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -898.16% | -577.30% | -38.39% | -376.39% | -92,466.67% |
| Cash from Investing | -724.59% | -132.63% | -21.28% | -829.16% | -95.08% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -7.29% | -74.87% | -94.26% | 618.35% | -14.66% |
| Repurchase of Common Stock | -- | -- | -- | -619.09% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -7.29% | -74.87% | -94.26% | 617.98% | -14.66% |
| Foreign Exchange rate Adjustments | -324.29% | 2,283.33% | -4,312.50% | 619.44% | -241.46% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -95.14% | -71.06% | -109.78% | 103.20% | 39.15% |
